Organogenesis Holdings Inc. (NASDAQ:ORGO) saw a downside of -18.38% to $9.84 after subtracting -$2.21 on Tuesday. The 5-day average trading volume is 1,795,644 shares of the company’s common stock. It has gained $13.60 in the past week. An average of 1,339,731 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,010,974.
ORGO’s 1-month performance is -27.97% or -$6.78 on its low of $9.90 reached on 10/12/21. The company’s shares have touched a 52-week low of $3.45 and high of $24.34, with the stock’s rally to the 52-week high happening on 04/09/21. YTD, ORGO has achieved 60.03% or $2.42. However, the current price is down -59.59%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Jul 19, 85 days have gone by since the last insider trading activity for Organogenesis Holdings Inc. (ORGO). Gillheeney Gary S. (President and CEO) most recently sold 160,237 shares at $14.02 per share on Jul 19. This transaction cost the insider $2,246,523. President and CEO, Gillheeney Gary S., sold 139,763 shares at a price of $14.74 on Jul 16. Then, on Jun 09, 10% Owner ERANI ALBERT sold 150,000 shares at a price of $15.31 per share. This transaction amounted to $2,296,500.
The company’s PE ratio for the last five years has touched a high of 162.00 and a low of 17.70. ORGO stock has a beta of 1.53. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.57 while the price-to-book (PB) in the most recent quarter is 8.61, with the price to cash flow ratio at 60.43.
Organogenesis Holdings Inc.’s quick ratio for the period ended June 29 was 2.10, with the current ratio over the same period at 2.40 meaning that ORGO stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.32, while the total debt to equity was 0.47. In terms of profitability, the gross margin trailing 12 months is 76.00%. The trailing 12-month EBITDA margin is 10.31% while for the period ending June 29; Organogenesis Holdings Inc.’s operating margin was 18.90%. The firm’s gross profit as reported stood at $250.98 million against revenue of $338.3 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected ORGO to announce $0.07 per share in earnings in its latest quarter, but it posted $0.15, representing a 114.30% surprise. EBITDA for the quarter stood at more than $27.33 million. ORGO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 176.64 million, with total debt at $112.2 million. Shareholders hold equity totaling $128.58 million
Let’s look briefly at Organogenesis Holdings Inc. (ORGO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 14.66% to suggest the stock is trending oversold, with historical volatility in this time period at 83.83%.
The stock’s 5-day moving average is $12.02, reflecting a -25.91% or -$3.48 change from its current price. ORGO is currently trading -31.71% above its 20-day SMA, -37.58% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -32.31% and +54.02% respectively.
Stochastic %K and %D was 3.48% and 5.55% and the average true range (ATR) pointed at 0.95. The RSI (14) points at 22.50%, while the 14-day stochastic is at 0.77% with the period’s ATR at 0.93. The stock’s 9-day MACD Oscillator is pointing at -1.19 and -2.09 on the 14-day charts.
In the most recent analyst report for Organogenesis Holdings Inc. (NASDAQ: ORGO), SVB Leerink launched coverage with an Outperform rating. Analysts offering their rating for ORGO stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ORGO as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is ORGO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $25.00 and a high of $29.00, with their median price target at $26.50. Looking at these predictions, the average price target given by analysts is for Organogenesis Holdings Inc. (ORGO) stock is $26.75.